Evidence map›Paper›PMID 41161572›Full record

ReviewJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance2025

Ferumoxytol-enhanced cardiovascular magnetic resonance imaging: applications and technical advances.

Kim-Lien Nguyen, Yue-Hin Loke, Jennifer M Li, Arash Bedayat, Hsin-Jung Yang, Yibin Xie, Anthony G Christodoulou, Debiao Li, Xiaodong Zhong, J Paul Finn

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Safety and TJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kim-Lien NguyenDivision of Cardiology, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, California, USA; Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA; Department of Bioengineering, University of California Los Angeles, Los Angeles, California, USA; Physics and Biology in Medicine Graduate Program, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Electronic address: klnguyen@ucla.edu.
Yue-Hin LokeDivision of Cardiology, Children's National Hospital, Washington, DC, USA.
Jennifer M LiDivision of Cardiology, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.
Arash BedayatDepartment of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Hsin-Jung YangBiomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Yibin XieBiomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Anthony G ChristodoulouDepartment of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA; Department of Bioengineering, University of California Los Angeles, Los Angeles, California, USA; Physics and Biology in Medicine Graduate Program, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Debiao LiDepartment of Bioengineering, University of California Los Angeles, Los Angeles, California, USA; Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Xiaodong ZhongDepartment of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA; Department of Bioengineering, University of California Los Angeles, Los Angeles, California, USA; Physics and Biology in Medicine Graduate Program, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
J Paul FinnDepartment of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA; Physics and Biology in Medicine Graduate Program, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Electronic address: pfinn@mednet.ucla.edu.

Funding

Expanding on a new paradigm for MRI in pediatric congenital heart diseaseR01HL127153 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHRISTODOULOU, ANTHONY G, FINN, JOHN PAUL · 2015 to 2024
$6.1M
Push-Button Cardiac MRI for Non-Invasive Quantification of Myocardial Energy Consumption in Heart FailureR01HL165211 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI Hsin-Jung Yang · 2022 to 2026
$3.9M
Ferumoxytol-Enhanced Cardiac MRI for Ischemic Heart DiseaseR01HL148182 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NGUYEN, KIM-LIEN T · 2020 to 2024
$3.8M
Cardiac MRI for Reperfusion Spatial Mapping to Improve Heart Failure OutcomesR01HL169695 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Kim-Lien T Nguyen · 2023 to 2026
$2.7M
SSFP Cardiovascular MR Imaging on 3.0T Using Unified-Coil Local ShimmingR01HL156818 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SPINCEMAILLE, PASCAL, YANG, HSIN-JUNG · 2021 to 2024
$2.5M
Fully Quantitative Low-Dose, Motion-Resolved Dynamic Contrast-Enhanced MRI in Pancreatic AdenocarcinomaR01EB032801 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Anthony G Christodoulou, Debiao Li · 2022 to 2026
$2.1M
CSRD VA I01 CX001901CSRD VA I01 CX002208NHLBI NIH HHS R01 HL127153NHLBI NIH HHS R01 HL148182NHLBI NIH HHS R01 HL156818NHLBI NIH HHS R01 HL165211NHLBI NIH HHS R01 HL169695NIBIB NIH HHS R01 EB032801
6 · The paper itself

Abstract

Magnetic resonance imaging with gadolinium chelates has transformed the diagnostic practice of cardiovascular medicine. From anatomic and functional cardiac imaging to myocardial tissue composition, vascular imaging, and blood flow measurement, the clinical benefits of contrast-enhanced cardiovascular magnetic resonance (CMR) are well established. Since their introduction over 40 years ago, gadolinium chelates have had an excellent safety track record; however, concerns related to gadolinium retention have prompted in-depth consideration of potential risks and benefits in some patient groups. Recently, ferumoxytol has emerged as an off-label, versatile blood-pool contrast agent for CMR. Endowed with high r

Indexed as

Cardiovascular DiseasesContrast MediaFerrosoferric OxideMagnetic Resonance ImagingAnimalsHumansPredictive Value of TestsContrast MediaFerrosoferric OxideCardiovascular magnetic resonanceFerumoxytolMagnetic resonance angiographyUSPIOVenography

Identifiers

PMID41161572
PMCPMC12766620

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.